PDCD1LG2 and plasma cell myeloma: To evaluate whether blocking PD-L1 and PD-L2 expression on RPMI8226 affects sensitivity of the myeloma cells to NK cell-mediated killing, RPMI8226 were first incubated with anti-PD-L1 or PD-L2 antibody before being added in the MTT assay as target cells.